CNSide Diagnostics, a subsidiary of Plus Therapeutics, has secured a significant payer coverage agreement with Highmark, effective April 1, 2026. This agreement extends reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay, which is crucial for patients suffering from metastatic central nervous system cancers. With Highmark joining the list of insurers that already includes United Healthcare and Humana, the total number of covered lives for the CNSide assay has increased from approximately 67 million to 75 million, moving the company closer to its goal of reaching 150 million covered lives by the end of 2026.

This development is particularly important for the longevity and healthspan research community as it enhances patient access to a diagnostic tool that has shown superior clinical utility over conventional CSF cytology. The CNSide assay has demonstrated high sensitivity (92%) and specificity (95%) in detecting leptomeningeal metastases, which can lead to earlier diagnosis and optimized treatment strategies. Moreover, health economic analyses indicate that its use can reduce healthcare costs associated with leptomeningeal metastases by around 40%, highlighting its potential to improve both clinical outcomes and economic efficiency in cancer care.

For professionals in the field, this agreement underscores the growing recognition of the CNSide assay’s clinical and economic value among payers. The expanded coverage could facilitate broader adoption in oncology centers, ultimately influencing treatment decisions and improving patient management in a challenging area of cancer care. As the landscape of cancer diagnostics evolves, the CNSide assay exemplifies the potential for innovative technologies to enhance patient outcomes and reshape treatment paradigms.

Source: globenewswire.com